Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-088140 · Präparat HOS-083615
Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of
nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin,
rifampicin, and trimethoprim/sulfamethoxazole. Ketoconazole and erythromycin significantly
inhibited the formation of nevirapine hydroxylated metabolites.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) ketoconazole (HOS-084513) erythromycin (HOS-084514) dapsone (HOS-088141) rifabutin (HOS-086262) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 287f611aa6814b77da2d4566909fd98bfac0e60816895edf476ea11c81f8affa · Zeichen 25397–25736 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 40
HOS-088231 · Präparat HOS-083615
Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of
nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin,
rifampicin, and trimethoprim/sulfamethoxazole. Ketoconazole and erythromycin significantly
inhibited the formation of nevirapine hydroxylated metabolites.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dapsone (HOS-088141) rifabutin (HOS-086262) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533) ketoconazole (HOS-084513) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 287f611aa6814b77da2d4566909fd98bfac0e60816895edf476ea11c81f8affa · Zeichen 25548–25887 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 66
HOS-088321 · Präparat HOS-083615
Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of
nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin,
rifampicin, and trimethoprim/sulfamethoxazole. Ketoconazole and erythromycin significantly
inhibited the formation of nevirapine hydroxylated metabolites.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) ketoconazole (HOS-084513) erythromycin (HOS-084514) dapsone (HOS-088141) rifabutin (HOS-086262) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 287f611aa6814b77da2d4566909fd98bfac0e60816895edf476ea11c81f8affa · Zeichen 25483–25822 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-088522 · Präparat HOS-083663
Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive
medicinal products (e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole,
amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also
increase the risk of adverse reactions to zidovudine. If concomitant therapy with Combivir and any of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ganciclovir (HOS-085194) vincristine (HOS-086219) vinblastine (HOS-086220) doxorubicin (HOS-084538) pentamidine (HOS-085605) dapsone (HOS-088141) pyrimethamine (HOS-088523) amphotericin (HOS-088524) flucytosine (HOS-088525)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 630f15f3aa0679e134693606ce8bb2db3318cda621afe444c3d4ca4706aeffef · Zeichen 11429–11818 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-108573 · Präparat HOS-093047
Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive
medicinal products (e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole,
amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also
increase the risk of adverse reactions to zidovudine (see section 4.8). If concomitant therapy with
Trizivir and any of these medicinal products is necessary then extra care should be taken in monitoring
renal function and haematological parameters and, if required, the dosage of one or more agents
should be reduced.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pentamidine (HOS-085605) dapsone (HOS-088141) pyrimethamine (HOS-088523) amphotericin (HOS-088524) flucytosine (HOS-088525) ganciclovir (HOS-085194) vincristine (HOS-086219) vinblastine (HOS-086220) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage fadf52ee0ecc448cf34162a118a4ee0bbbc7fa1f124c0cc7fa32c024f4ee7a11 · Zeichen 16340–16946 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26
HOS-108940 · Präparat HOS-093083
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of
contraception must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after
levothyroxine. starting and/or ending
lopinavir/ritonavir treatment.
Vasodilating agents
25
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should
AUC: ↑ 5-fold be closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of co-administration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bosentan (HOS-086291) riociguat (HOS-086293) dapsone (HOS-088141) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533) azithromycin (HOS-088112) fluconazole (HOS-087945) methadone (HOS-086198) bupropion (HOS-086329) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8d752c4274572732732b0956ff6ff26c5cf23921c5ef2d225aedad5e185afa6d · Zeichen 59817–63890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61
HOS-109024 · Präparat HOS-093083
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone (TSH)
reported indicating a potential should be monitored in patients
interaction between ritonavir treated with levothyroxine at least the
containing products and first month after starting and/or
levothyroxine. ending lopinavir/ritonavir treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with bosentan.
concentrations may decrease due When Kaletra is administered
to CYP3A4 induction by concomitantly with bosentan, the
bosentan. efficacy of the HIV therapy should
be monitored and patients should be
Bosentan: closely observed for bosentan
AUC: ↑ 5-fold toxicity, especially during the first
Cmax: ↑ 6-fold week of co-administration.
Initially, bosentan Cmin: ↑ by
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and P-gp with Kaletra is not recommended
inhibition by lopinavir/ritonavir. (see section 4.4 and refer to riociguat
SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) dapsone (HOS-088141) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533) azithromycin (HOS-088112) fluconazole (HOS-087945) levothyroxine (HOS-086339) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 65f5a6f4d7302840533b08e744ce8d52c7c6cce98bf349aa71cfb302b25446dd · Zeichen 59068–61276 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 96–97
HOS-109102 · Präparat HOS-093083
96
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after starting
levothyroxine. and/or ending lopinavir/ritonavir
treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should be
AUC: ↑ 5-fold closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of coadministration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) levothyroxine (HOS-086339) bosentan (HOS-086291) riociguat (HOS-086293) dapsone (HOS-088141) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533) azithromycin (HOS-088112) fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage eb717f7573e257a0db9660c2692fa6be3f81b8ac5b4c1043b1f49219b74ffa31 · Zeichen 58967–62731 im Abschnitt
Wechselwirkungen · Pegasys
Pegasys 90 micrograms solution for injection in pre-filled syringe Pegasys 135 micrograms solution for injection in pre-filled syringe Pegasys 180 micrograms solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 16
HOS-109800 · Präparat HOS-093265
Administration of Pegasys 180 micrograms once weekly for 4 weeks in healthy male subjects did not
show any effect on mephenytoin, dapsone, debrisoquine and tolbutamide pharmacokinetics profiles,
suggesting that Pegasys has no effect on in vivo metabolic activity of cytochrome P450 3A4, 2C9,
2C19 and 2D6 isozymes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mephenytoin (HOS-109801) dapsone (HOS-088141) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 6921e4ecb62ea38e68c21619fcbf65559f33fc1f4b31a27ac996e27a8bfd58e9 · Zeichen 57–371 im Abschnitt
Wechselwirkungen · Pegasys
Pegasys 180 micrograms solution for injection · Abschnitt 4.5 · PDF-Seite 54
HOS-109865 · Präparat HOS-093265
Administration of Pegasys 180 micrograms once weekly for 4 weeks in healthy male subjects did not
show any effect on mephenytoin, dapsone, debrisoquine and tolbutamide pharmacokinetics profiles,
suggesting that Pegasys has no effect on in vivo metabolic activity of cytochrome P450 3A4, 2C9,
2C19 and 2D6 isozymes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mephenytoin (HOS-109801) dapsone (HOS-088141) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 6921e4ecb62ea38e68c21619fcbf65559f33fc1f4b31a27ac996e27a8bfd58e9 · Zeichen 57–371 im Abschnitt
Wechselwirkungen · Fuzeon
Fuzeon 90 mg/ml powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 4
HOS-112395 · Präparat HOS-093667
Influence of enfuvirtide on metabolism of concomitant medicinal products: In an in-vivo human
metabolism study enfuvirtide, at the recommended dose of 90 mg twice daily, did not inhibit the
metabolism of substrates by CYP3A4 (dapsone), CYP2D6 (debrisoquine), CYP1A2 (caffeine),
CYP2C19 (mephenytoin), and CYP2E1 (chlorzoxazone).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): chlorzoxazone (HOS-112397) dapsone (HOS-088141) caffeine (HOS-085902) mephenytoin (HOS-109801)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-23T14:24:00Z · SHA-256 e89d317a43084b88c577a5e2fa9e8f995c2b6672ed7d5ae08eb316c0043e17cf · Passage 185be7500394c4d30c408d9477ae585640a87432f19f62a7a099572909dfabcf · Zeichen 220–548 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-116820 · Präparat HOS-094481
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
In vitro the following May increase tacrolimus whole Monitor tacrolimus whole
substances have been shown blood trough concentrations and blood trough concentrations
to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if
tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed [see section 4.2].
bromocriptine, cortisone, prolongation) [see section 4.4]. Monitor renal function, ECG
dapsone, ergotamine, for QT prolongation, and other
gestodene, lidocaine, side effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that
rifampicin, phenytoin, blood trough concentrations and concomitant use should be
carbamazepine, apalutamide, increase the risk of rejection [see avoided. If unavoidable,
enzalutamide, mitotane, or section 4.4]. patients may require an
St. John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose.
perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose
weeks after co-administration. The should be individualized and
effect may remain 1-2 weeks after adjusted as needed based on
completion of the treatment. tacrolimus trough
concentrations, which should
be assessed at initiation,
monitored frequently
throughout (starting within the
first few days) and re-
evaluated on and after
completion of the CYP3A4
inducer. After use of the
CYP3A4 inducer has ended,
tacrolimus dose may need to
be adjusted gradually. Monitor
graft function closely.
Moderate CYP3A4 inducers: May decrease tacrolimus whole Monitor tacrolimus whole
metamizole, phenobarbital, blood trough concentrations and blood trough concentrations
isoniazid, rifabutin, increase the risk of rejection [see and increase tacrolimus dose if
efavirenz, etravirine, section 4.4]. needed [see section 4.2].
nevirapine; weak CYP3A4 Monitor graft function closely.
inducers: flucloxacillin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tamoxifen (HOS-088380) phenytoin (HOS-084531) bromocriptine (HOS-090620) cortisone (HOS-114161) dapsone (HOS-088141) ergotamine (HOS-086154) gestodene (HOS-116824) lidocaine (HOS-108866) mephenytoin (HOS-109801) midazolam (HOS-086167) nilvadipine (HOS-116826) quinidine (HOS-085593) carbamazepine (HOS-085618) apalutamide (HOS-086212) enzalutamide (HOS-116829) mitotane (HOS-112479) phenobarbital (HOS-085617) isoniazid (HOS-088590) rifabutin (HOS-086262) efavirenz (HOS-087947) etravirine (HOS-088088) nevirapine (HOS-088064)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 9f68b7412442537a87ae5cc4a11a2083ae7ee1d4f84bacfd72b3336085546560 · Zeichen 8467–12012 im Abschnitt
Wechselwirkungen · Besremi
Besremi 250 micrograms/0.5 mL solution for injection in pre-filled pen Besremi 500 micrograms/0.5 mL solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 7
HOS-135517 · Präparat HOS-097722
Administration of 180 micrograms of pegylated interferon alfa-2a once weekly for 4 weeks in healthy
male subjects did not show any effect on mephenytoin, dapsone, debrisoquine and tolbutamide
pharmacokinetics profiles, suggesting that pegylated interferon alfa-2a has no effect on in vivo
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): interferon alfa-2a (HOS-135516) mephenytoin (HOS-109801) dapsone (HOS-088141) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-24T15:08:00Z · SHA-256 b821a9d463d0e9f05f3c2788ab2015a721e1b4a1ebc9433fe4d8072c0d2af2de · Passage 87e33076b8ee44cf55348e7c7ab5e57661fb380a31b8c9983a0abae76dc764f8 · Zeichen 761–1049 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 12–13
HOS-139170 · Präparat HOS-098290
12
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
In vitro the following May increase tacrolimus whole Monitor tacrolimus whole
substances have been shown blood trough concentrations and blood trough concentrations
to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if
tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed (see section 4.2).
bromocriptine, cortisone, prolongation) (see section 4.4). Monitor renal function, ECG
dapsone, ergotamine, for QT prolongation, and other
gestodene, lidocaine, side effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen.
Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that
rifampicin, phenytoin, blood trough concentrations and concomitant use should be
carbamazepine, apalutamide, increase the risk of rejection (see avoided. If unavoidable,
enzalutamide, mitotane, or St. section 4.4). patients may require an
John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose.
perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose
weeks after co-administration. The should be individualized and
effect may remain 1-2 weeks after adjusted as needed based on
completion of the treatment. tacrolimus trough
concentrations, which should
be assessed at initiation,
monitored frequently
throughout (starting within the
first few days) and re-
evaluated on and after
completion of the CYP3A4
inducer. After use of the
CYP3A4 inducer has ended,
tacrolimus dose may need to
be adjusted gradually. Monitor
graft function closely.
Moderate CYP3A4 inducers: May decrease tacrolimus whole Monitor tacrolimus whole
metamizole, phenobarbital, blood trough concentrations and blood trough concentrations
isoniazid, rifabutin, efavirenz, increase the risk of rejection (see and increase tacrolimus dose if
etravirine, nevirapine section 4.4). needed (see section 4.2).
Weak CYP3A4 inducers: Monitor graft function closely.
flucloxacillin
Caspofungin May decrease tacrolimus whole Monitor tacrolimus whole
blood trough concentrations and blood trough concentrations
increase the risk of rejection. and increase tacrolimus dose if
Mechanism of interaction has not needed (see section 4.2).
been confirmed. Monitor graft function closely.
Cannabidiol (P-gp inhibitor) There have been reports of Tacrolimus and cannabidiol
increased tacrolimus blood levels should be co-administered with
during concomitant use of caution, closely monitoring for
tacrolimus with cannabidiol. This side effects. Monitor
may be due to inhibition of tacrolimus whole blood trough
intestinal P-glycoprotein, leading to concentrations and adjust the
increased bioavailability of tacrolimus dose if needed (see
tacrolimus. sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) bromocriptine (HOS-090620) cortisone (HOS-114161) dapsone (HOS-088141) ergotamine (HOS-086154) gestodene (HOS-116824) lidocaine (HOS-108866) mephenytoin (HOS-109801) midazolam (HOS-086167) nilvadipine (HOS-116826) quinidine (HOS-085593) tamoxifen (HOS-088380) carbamazepine (HOS-085618) apalutamide (HOS-086212) enzalutamide (HOS-116829) mitotane (HOS-112479) phenobarbital (HOS-085617) isoniazid (HOS-088590) rifabutin (HOS-086262) efavirenz (HOS-087947) etravirine (HOS-088088) nevirapine (HOS-088064) caspofungin (HOS-109306) cannabidiol (HOS-090609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage fa1f35020c5c33f04f1dedfbde5310972baf1c60d65f0f37f47f320487c85aab · Zeichen 8700–13685 im Abschnitt
Wechselwirkungen · Doptelet
Doptelet 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-140826 · Präparat HOS-098586
Medicinal products used in the treatment of ITP in combination with avatrombopag in clinical trials
included corticosteroids, danazol, dapsone, and intravenous immunoglobulin (IVIg). Platelet counts
should be monitored when combining avatrombopag with other medicinal products for the treatment
of ITP in order to avoid platelet counts outside of the recommended range.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473) dapsone (HOS-088141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-18T16:42:00Z · SHA-256 4aa299702805434ebd4ea8b3427376fdfed980657ef6db01eab3f2ed8a813c1d · Passage 81c350b273746ac8dac08de77832b4fdef1a525e9d43f4c31d9a18a9aaaf0c51 · Zeichen 2661–3030 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.